These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20307200)

  • 1. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
    Belani CP
    Cancer Invest; 2010 May; 28(4):413-23. PubMed ID: 20307200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Riely GJ
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIBW 2992 in non-small cell lung cancer.
    Subramaniam DS; Hwang J
    Expert Opin Investig Drugs; 2011 Mar; 20(3):415-22. PubMed ID: 21320004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
    Piotrowska Z; Sequist LV
    Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
    Karachaliou N; Rosell R; Morales-Espinosa D; Viteri S
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):807-15. PubMed ID: 24611674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
    Peters S; Zimmermann S; Adjei AA
    Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
    Morabito A; Costanzo R; Rachiglio AM; Pasquale R; Sandomenico C; Franco R; Montanino A; De Lutio E; Rocco G; Normanno N
    J Thorac Oncol; 2013 Jul; 8(7):e59-60. PubMed ID: 23774386
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
    Tartarone A; Lerose R
    Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
    Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Myerson JS; Iqbal SA; O'Brien ME; Popat S
    Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
    Brzezniak C; Carter CA; Giaccone G
    Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
    Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
    Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.